TG Therapeutics (NASDAQ:TGTX) Given New $49.00 Price Target at JPMorgan Chase & Co.

TG Therapeutics (NASDAQ:TGTX) had its price objective lifted by JPMorgan Chase & Co. from $46.00 to $49.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 49.02% from the company’s current price.

A number of other research firms have also issued reports on TGTX. The Goldman Sachs Group upgraded TG Therapeutics to a “hold” rating and set a $37.00 price objective for the company in a research report on Thursday, July 10th. B. Riley upped their price target on TG Therapeutics from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of TG Therapeutics in a research report on Wednesday, October 8th. Finally, HC Wainwright assumed coverage on TG Therapeutics in a research note on Monday, October 6th. They issued a “buy” rating and a $60.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $50.25.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX traded down $1.90 during trading on Monday, reaching $32.88. The stock had a trading volume of 2,665,259 shares, compared to its average volume of 2,348,264. TG Therapeutics has a one year low of $22.92 and a one year high of $46.48. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The stock has a market cap of $5.22 billion, a PE ratio of 88.98 and a beta of 1.97. The firm’s 50 day moving average price is $33.45 and its two-hundred day moving average price is $34.81.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $2.19. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business had revenue of $161.71 million during the quarter, compared to the consensus estimate of $152.12 million. During the same period in the previous year, the business earned $0.02 EPS. The business’s quarterly revenue was up 92.7% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts forecast that TG Therapeutics will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the completion of the transaction, the director owned 94,061 shares of the company’s stock, valued at $3,032,526.64. This represents a 18.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 10.64% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Ameritas Advisory Services LLC acquired a new stake in TG Therapeutics during the 2nd quarter valued at $25,000. Johnson Financial Group Inc. acquired a new stake in TG Therapeutics during the 2nd quarter valued at $25,000. Salomon & Ludwin LLC acquired a new stake in TG Therapeutics during the 3rd quarter valued at $34,000. Stone House Investment Management LLC acquired a new stake in TG Therapeutics during the 3rd quarter valued at $36,000. Finally, SVB Wealth LLC acquired a new stake in TG Therapeutics during the 1st quarter valued at $37,000. 58.58% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.